1 / 23

Global Next Generation Gynecological Cancer Diagnostics Market

Next-Generation Gynecological Cancer Diagnostics market to grow at a significant CAGR of 10.07% during 2020-2031.The Market is expected to reach $5,657.7 Million by 2031. Next-Generation Gynecological Cancer Diagnostics market report by BIS Research provides deep market insight, industry analysis, trends & forecast to 2031 that will help your business to grow.

bisreports
Download Presentation

Global Next Generation Gynecological Cancer Diagnostics Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. res Next-Generation Gynecological Cancer Diagnostics Market - A Global Market and Regional Analysis Table of Content GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET https://www.freepik.com/premium-vector/dna-strand-molecular-structure-genetic-engineering-laboratory-research_4927901.htm Focus on Technology, Product Type, End User, and Country Analysis Analysis and Forecast: 2020-2031 February 2022 1 All rights reserved at BIS Research Inc.

  2. BIS Research is a leading market intelligence and technology research company. BIS Research publishes in- depth market intelligence reports focusing on the market estimations, technology analysis, emerging high- growth applications, deeply segmented granular country-level market data and other important market parameters useful in the strategic decision making for senior management. BIS Research provides multi-client reports, company profiles, databases, and custom research services. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET Copyright © 2022 BIS Research Inc. All Rights Reserved. This document contains highly confidential information and is the sole property of BIS Research. Disclosing, copying, circulating, quoting or otherwise reproducing any or all contents of this document is strictly prohibited. Access to this information is provided exclusively for the benefit of the people or organization concerned. It may not be accessed by or offered whether for sale or otherwise to any third party. 2 All rights reserved at BIS Research Inc.

  3. Table of Content 1.Definition .................................................................................. 27 1.1 Inclusion and Exclusion Criteria .................................................................... 27 1.1.1Inclusions ..................................................................................................... 27 1.1.2Exclusions ................................................................................................... 27 2.Research Scope ....................................................................... 28 Key Questions Answered in the Report ........................................................ 29 3.Research Methodology ............................................................. 30 2.1 3.1 Global Next-Generation Gynecological Cancer Diagnostics Market: Research Methodology ................................................................................... 30 3.2 Data Sources .................................................................................................... 31 3.2.1Primary Data Sources ................................................................................. 31 3.2.2Secondary Data Sources ............................................................................ 32 3.3 Market Estimation Model................................................................................. 32 GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET Criteria for Company Profiling ........................................................................ 34 4.Market ...................................................................................... 35 3.4 4.1 Introduction ...................................................................................................... 36 4.2 Molecular Profiling and Techniques .............................................................. 37 4.3 Role of Molecular Diagnostics in Gynecological Cancers ........................... 39 4.4 Diagnostic Technologies and Regulatory Landmarks Timeline in Gynecological Cancers ................................................................................... 40 4.5 Emerging Molecular Testing in Gynecological Cancer ................................ 41 Current Market Size and Growth Potential, $Million, 2021-2031 .................. 45 5.Role of Biomarkers in Gynecological Cancer ............................. 47 4.6 5.1 Introduction ...................................................................................................... 47 5.2 Predictive Molecular Testing in Gynecological Cancer ............................... 48 Companion Diagnostics (CDx) ....................................................................... 49 6.COVID-19 Impact on Global Next-Generation Gynecological Cancer Diagnostics Market ...................................................... 51 5.3 6.1 Impact on Supply Chain and Operations ....................................................... 51 3 All rights reserved at BIS Research Inc.

  4. 6.2 COVID-19 Impact: Global Next-Generation Gynecological Cancer Diagnostics Market .......................................................................................... 53 Pre- and Post-COVID-19 Impact Assessment ............................................... 54 7.Market Dynamics ...................................................................... 55 6.3 7.1 Overview ........................................................................................................... 55 7.2 Impact Analysis ............................................................................................... 56 7.3 Market Drivers .................................................................................................. 56 7.3.1Subsequent Decline in Next-Generation Sequencing (NGS) Cost .......... 56 7.3.2Increased Recommendations from Government Organizations and Scientific Societies ...................................................................................... 57 7.3.3Increased Awareness and Shift Toward Personalized Medicine............. 57 7.4 Market Restraints ............................................................................................. 59 7.4.1Limited Food and Drug Administration (FDA) Approved Next- Generation Sequencing (NGS) tests .......................................................... 59 GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET 7.4.2Complexities Involved with Overall Next-Generation Sequencing (NGS) Process and Result Interpretation .................................................. 59 7.4.3Reimbursement Challenges Across the Countries .................................. 61 7.5 Market Opportunities ....................................................................................... 61 7.5.1Increased Market Investments and Government Funded Projects ......... 61 7.5.2Next-Generation Sequencing (NGS) Acceptance by Emerging Nations ......................................................................................................... 62 8.Industry Insights ....................................................................... 63 8.1 Overview ........................................................................................................... 63 8.2 Legal Requirements and Framework in the U.S. ........................................... 63 8.2.1FDA Regulation............................................................................................ 63 8.2.2CMS Regulation ........................................................................................... 64 8.3 Legal Requirements and Framework in Europe ............................................ 65 8.4 Legal Requirements and Framework in Asia-Pacific .................................... 66 8.4.1China ............................................................................................................ 66 8.4.2Japan ............................................................................................................ 66 8.5 Reimbursement Scenario................................................................................ 67 4 All rights reserved at BIS Research Inc.

  5. Funding Scenario ............................................................................................ 70 9.Market Segmentation ............................................................... 71 8.6 9.1 Global Next-Generation Gynecological Cancer Diagnostics Market (by Technology), $Million, 2020-2031 ................................................................... 72 9.1.1Overview ...................................................................................................... 72 9.1.1.1 Polymerase Chain Reaction (PCR) .................................................................. 73 9.1.1.1.1by Value ................................................................................................................... 73 9.1.1.1.2by Volume ................................................................................................................ 74 9.1.1.2 Next-Generation Sequencing (NGS) ................................................................ 75 9.1.1.2.1by Value ................................................................................................................... 76 9.1.1.2.2by Volume ................................................................................................................ 76 9.1.1.2.3Broad Panels ............................................................................................................ 77 9.1.1.2.3.1by Value ............................................................................................................ 77 9.1.1.2.3.2by Volume ......................................................................................................... 78 GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET 9.1.1.2.4Targeted Gene Panels ............................................................................................. 79 9.1.1.2.4.1by Value ............................................................................................................ 79 9.1.1.2.4.2by Volume ......................................................................................................... 80 9.1.1.2.5Single Gene Panels ................................................................................................. 80 9.1.1.2.5.1by Value ............................................................................................................ 80 9.1.1.2.5.2by Volume ......................................................................................................... 81 9.1.1.3 Other Technologies .......................................................................................... 82 9.1.1.3.1by Value ................................................................................................................... 82 9.1.1.3.2by Volume ................................................................................................................ 83 10.Global Next-Generation Gynecological Cancer Diagnostics Market (by Product Type), $Million, 2020-2031 .......................... 84 10.1Overview ........................................................................................................... 84 10.2Services ............................................................................................................ 85 10.3Products ........................................................................................................... 86 11.Global Next-Generation Gynecological Cancer Diagnostics Market (by Indication), $Million, 2020-2031 ............................... 88 5 All rights reserved at BIS Research Inc.

  6. 11.1Overview ........................................................................................................... 88 11.2Ovarian Cancer ................................................................................................ 89 11.3Cervical Cancer ................................................................................................ 90 11.4Uterine Cancer ................................................................................................. 91 12.Global Next-Generation Gynecological Cancer Diagnostics Market (by End User), $Million, 2020-2031 ................................ 92 12.1Overview ........................................................................................................... 92 12.2Academic and Research Institutes ................................................................ 93 12.3Hospitals and Ambulatory Centers ................................................................ 94 12.4Diagnostic Laboratories .................................................................................. 95 12.5Other End Users .............................................................................................. 96 13.Global Next-Generation Gynecological Cancer Diagnostics Market (by Region), $Million, 2020-2031 .................................... 97 13.1Overview ........................................................................................................... 97 GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET 13.2North America ................................................................................................ 100 13.2.1U.S. ............................................................................................................. 103 13.2.2Canada ....................................................................................................... 104 13.3Europe ............................................................................................................ 106 13.3.1Germany ..................................................................................................... 109 13.3.2U.K. ............................................................................................................. 110 13.3.3France ......................................................................................................... 111 13.3.4Italy ............................................................................................................. 112 13.3.5Spain ........................................................................................................... 114 13.3.6Netherlands ................................................................................................ 115 13.3.7Rest-of-Europe........................................................................................... 116 13.4Asia-Pacific .................................................................................................... 117 13.4.1China .......................................................................................................... 119 13.4.2Japan .......................................................................................................... 121 13.4.3India ............................................................................................................ 122 13.4.4Australia ..................................................................................................... 123 6 All rights reserved at BIS Research Inc.

  7. 13.4.5South Korea ............................................................................................... 124 13.4.6Rest-of-Asia-Pacific ................................................................................... 125 13.5Latin America ................................................................................................. 126 13.5.1Brazil ........................................................................................................... 129 13.5.2Mexico ........................................................................................................ 130 13.5.3Rest-of-Latin America ............................................................................... 131 13.6Rest-of-the-World (RoW) ............................................................................... 132 14.Competitive Landscape and Company Profiles ........................ 133 14.1Competitive Landscape ................................................................................ 134 14.2Regulatory and Legal Activities ................................................................... 134 14.3Synergistic Activities .................................................................................... 135 14.4Mergers and Acquisitions ............................................................................. 136 14.5Product Launches ......................................................................................... 137 14.6Business Expansions .................................................................................... 138 GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET 14.7Market Share Analysis, by Service Providers, 2020 ................................... 139 14.8Market Share Analysis, by Product Manufacturers, 2020 .......................... 141 14.9Growth Share Analysis, by Company, 2019-2020 ....................................... 142 14.9.1Growth Share Analysis, by Service Providers, 2019-2020 ..................... 142 14.9.2Growth Share Analysis, by Product Manufacturers, 2019-2020 ............ 143 15.Company Profiles ................................................................... 145 15.1Overview ......................................................................................................... 145 15.2Agilent Technologies, Inc. ............................................................................ 146 15.2.1Company Overview ................................................................................... 146 15.2.2Role of Agilent Technologies, Inc. in the Global Next-Generation Gynecological Cancer Diagnostics Market ............................................. 146 15.2.3Key Customers of the Company .............................................................. 146 15.2.4Key Competitors of the Company ............................................................ 147 15.2.5Financials ................................................................................................... 148 15.2.6Key Insights About Financial Health of the Company ........................... 150 15.2.7Business Strategies .................................................................................. 150 7 All rights reserved at BIS Research Inc.

  8. 15.2.8SWOT Analysis .......................................................................................... 151 15.3ARUP Laboratories ........................................................................................ 152 15.3.1Company Overview ................................................................................... 152 15.3.2Role of ARUP Laboratories in the Global Next-generation gynecological Cancer Diagnostics Market .............................................. 152 15.3.3Key Customers of the Company .............................................................. 152 15.3.4Key Competitors of the Company ............................................................ 153 15.3.5SWOT Analysis .......................................................................................... 154 15.4BGI Genomics ................................................................................................ 155 15.4.1Company Overview ................................................................................... 155 15.4.2Role of BGI Genomics in the Global Next-Generation Gynecological Cancer Diagnostics Market ...................................................................... 155 15.4.3Key Customers of the Company .............................................................. 155 15.4.4Key Competitors of the Company ............................................................ 156 GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET 15.4.5Business Strategies .................................................................................. 156 15.4.6SWOT Analysis .......................................................................................... 157 15.5CENTOGENE N.V. .......................................................................................... 158 15.5.1Company Overview ................................................................................... 158 15.5.2Role of CENTOGENE N.V. in the Global Next-Generation Gynecological Cancer Diagnostics Market ............................................. 158 15.5.3Key Customers of the Company .............................................................. 158 15.5.4Key Competitors of the Company ............................................................ 159 15.5.5Financials ................................................................................................... 160 15.5.6Key Insights About Financial Health of the Company ........................... 162 15.5.7SWOT Analysis .......................................................................................... 163 15.6F. Hoffmann-La Roche Ltd ............................................................................ 164 15.6.1Company Overview ................................................................................... 164 15.6.2Role of F. Hoffmann-La Roche Ltd in the Global Next-Generation Gynecological Cancer Diagnostics Market ............................................. 164 15.6.3Key Customers of the Company .............................................................. 164 15.6.4Key Competitors of the Company ............................................................ 165 8 All rights reserved at BIS Research Inc.

  9. 15.6.5Financials ................................................................................................... 166 15.6.6Key Insights About Financial Health of the Company ........................... 168 15.6.7Business Strategies .................................................................................. 168 15.6.8SWOT Analysis .......................................................................................... 169 15.7Fulgent Genetics, Inc. ................................................................................... 170 15.7.1Company Overview ................................................................................... 170 15.7.2Key Customers of the Company .............................................................. 170 15.7.3Key Competitors of the Company ............................................................ 171 15.7.4Financials ................................................................................................... 172 15.7.5Key Insights About Financial Health of the Company ........................... 173 15.7.6Business Strategies .................................................................................. 173 15.7.7SWOT Analysis .......................................................................................... 174 15.8Illumina, Inc. ................................................................................................... 175 15.8.1Company Overview ................................................................................... 175 GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET 15.8.2Role of Illumina, Inc. in the Global Next-Generation Gynecological Cancer Diagnostics Market ...................................................................... 175 15.8.3Key Customers of the Company .............................................................. 175 15.8.4Key Competitors of the Company ............................................................ 176 15.8.5Financials ................................................................................................... 177 15.8.6Key Insights About Financial Health of the Company ........................... 179 15.8.7SWOT Analysis .......................................................................................... 180 15.9Invitae Corporation ........................................................................................ 181 15.9.1Company Overview ................................................................................... 181 15.9.2Role of Invitae Corporation in the Global Next-Generation Gynecological Cancer Diagnostics Market ............................................. 181 15.9.3Key Customers of the Company .............................................................. 181 15.9.4Key Competitors of the Company ............................................................ 182 15.9.5Financials ................................................................................................... 183 15.9.6Key Insights About Financial Health of the Company ........................... 185 15.9.7Business Strategies .................................................................................. 185 9 All rights reserved at BIS Research Inc.

  10. 15.9.8SWOT Analysis .......................................................................................... 186 15.10Konica Minolta, Inc. ....................................................................................... 187 15.10.1 Company Overview ............................................................................. 187 15.10.2 Role of Konica Minolta, Inc. in the Global Next-Generation Gynecological Cancer Diagnostics Market ............................................. 187 15.10.3 Key Customers of the Company ........................................................ 187 15.10.4 Key Competitors of the Company ..................................................... 188 15.10.5 Financials ............................................................................................ 189 15.10.6 Key Insights About Financial Health of the Company ..................... 191 15.10.7 Business Strategies ............................................................................ 191 15.10.8 SWOT Analysis.................................................................................... 192 15.11Laboratory Corporation of America Holdings ............................................. 193 15.11.1 Company Overview ............................................................................. 193 15.11.2 Role of Laboratory Corporation of America Holdings in the Global Next-Generation Gynecological Cancer Diagnostics Market .... 193 GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET 15.11.3 Key Customers of the Company ........................................................ 193 15.11.4 Key Competitors of the Company ..................................................... 194 15.11.5 Financials ............................................................................................ 195 15.11.6 Business Strategies ............................................................................ 196 15.11.7 SWOT Analysis.................................................................................... 197 15.12Myriad Genetics, Inc. ..................................................................................... 198 15.12.1 Company Overview ............................................................................. 198 15.12.2 Role of Myriad Genetics, Inc. in the Global Next-Generation Gynecological Cancer Diagnostics Market ............................................. 198 15.12.3 Key Customers of the Company ........................................................ 198 15.12.4 Key Competitors of the Company ..................................................... 199 15.12.5 Financials ............................................................................................ 200 15.12.6 SWOT Analysis.................................................................................... 201 15.13OPKO Health, Inc. .......................................................................................... 202 15.13.1 Company Overview ............................................................................. 202 10 All rights reserved at BIS Research Inc.

  11. 15.13.2 Role of OPKO Health, Inc. in the Global Next-Generation Gynecological Cancer Diagnostics Market ............................................. 202 15.13.3 Key Customers of the Company ........................................................ 202 15.13.4 Key Competitors of the Company ..................................................... 203 15.13.5 Financials ............................................................................................ 204 15.13.6 Key Insights About Financial Health of the Company ..................... 206 15.13.7 SWOT Analysis.................................................................................... 207 15.14QIAGEN N.V .................................................................................................... 208 15.14.1 Company Overview ............................................................................. 208 15.14.2 Role of QIAGEN N.V. in the Global Next-Generation Gynecological Cancer Diagnostics Market ............................................. 208 15.14.3 Key Customers of the Company ........................................................ 208 15.14.4 Key Competitors of the Company ..................................................... 209 15.14.5 Financials ............................................................................................ 210 GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET 15.14.6 Key Insights About Financial Health of the Company ..................... 212 15.14.7 Business Strategies ............................................................................ 212 15.14.8 SWOT Analysis.................................................................................... 213 15.15Quest Diagnostics Incorporated .................................................................. 214 15.15.1 Company Overview ............................................................................. 214 15.15.2 Role of Quest Diagnostics Incorporated in the Global Next- Generation Gynecological Cancer Diagnostics Market ......................... 214 15.15.3 Key Customers of the Company ........................................................ 214 15.15.4 Key Competitors of the Company ..................................................... 215 15.15.5 Financials ............................................................................................ 216 15.15.6 SWOT Analysis.................................................................................... 217 15.16Thermo Fisher Scientific Inc. ........................................................................ 218 15.16.1 Company Overview ............................................................................. 218 15.16.2 Role of Thermo Fisher Scientific Inc. in the Global Next- Generation Gynecological Cancer Diagnostics Market ......................... 218 15.16.3 Key Customers of the Company ........................................................ 218 15.16.4 Key Competitors of the Company ..................................................... 219 11 All rights reserved at BIS Research Inc.

  12. 15.16.5 Financials ............................................................................................ 220 15.16.6 Key Insights About Financial Health of the Company ..................... 222 SWOT Analysis.................................................................................... 223 Emerging companies .................................................................... 224 15.16.7 15.17Overview ......................................................................................................... 224 15.18NgeneBio ........................................................................................................ 224 15.18.1 Company Overview ............................................................................. 224 15.18.2 Role of NgeneBio in the Global Next-Generation Gynecological Cancer Diagnostics Market ...................................................................... 224 15.19oncgnostics GmbH ........................................................................................ 225 15.19.1 Company Overview ............................................................................. 225 15.19.2 Role of oncgnostics GmbH in the Global Next-Generation Gynecological Cancer Diagnostics Market ............................................. 225 15.20Self-screen B.V. ............................................................................................. 226 GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET 15.20.1 Company Overview ............................................................................. 226 15.20.2 Role of Self-screen B.V. in the Global Next-Generation Gynecological Cancer Diagnostics Market ............................................. 226 15.21Strata Oncology, Inc. ..................................................................................... 227 15.21.1 Company Overview ............................................................................. 227 15.21.2 Role of Strata Oncology, Inc. in the Global Next-Generation Gynecological Cancer Diagnostics Market ............................................. 227 12 All rights reserved at BIS Research Inc.

  13. List of Figures Figure 1: Impact Analysis of Market Drivers and Opportunities in Global Next-Generation Gynecological Cancer Diagnostics Market Figure 2: Global Next-Generation Gynecological Cancer Diagnostics Market (by Technology), 2020 and 2031 Figure 3: Global Next-Generation Gynecological Cancer Diagnostics Market (by Product Type), 2020 and 2031 Figure 4: Global Next-Generation Gynecological Cancer Diagnostics Market (by Indication), 2020 and 2031 Figure 5: Global Next-Generation Gynecological Cancer Diagnostics Market (by End User), 2020 and 2031 Figure 6: Global Next-Generation Gynecological Cancer Diagnostics Market (by Region), 2020-2031 Figure 7: Global Next-Generation Gynecological Cancer Diagnostics Market Segmentation Figure 8: Figure: Global Next-Generation Gynecological Cancer Diagnostics Market: Methodology Figure 9: Figure: Bottom-Up Approach (Segment-Wise Analysis) GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET Figure 10: Figure: Top-Down Approach (Segment-Wise Analysis) Figure 11: Cervical Cancer, Incidence Cases and New Cases (2008-2018) Figure 12: Ovarian Cancer, Incidence Cases and New Cases (2008-2018) Figure 13: Molecular Diagnostics Evolution Timeline Figure 14: Types of Molecular Diagnostics Technologies Figure 15: Diagnostic Technologies and Regulatory Landmark Timeline Figure 16: Type of Non-Invasive Next Generation Novel Molecular Diagnostics Figure 17: Evolution of Sequencing Technologies Figure 18: Difference Between Polymerase Chain reaction (PCR) Across Three Generation Sequencing Figure 19: Global Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031 Figure 20: Potential Biomarkers for Gynecological Cancer Detection Figure 21: Number of Food and Drug Administration (FDA) Approved Companion Diagnostics (CDx), (1998–2020) Figure 22: Number of Food and Drug Administration (FDA) Approved Companion Diagnostics (CDx) Assays by Analytical Platform/Technology Figure 23: Laboratory Setting and Testing Methodologies Being Adopted by the Respondent’s Laboratories Figure 24: Types of Molecular Testing for Cancer Performed 13 All rights reserved at BIS Research Inc.

  14. Figure 25: Global Next-Generation Gynecological Cancer Diagnostics Market: COVID-19 Impact Figure 26: Impact of COVID-19 on Global Next-Generation Gynecological Cancer Diagnostics Market Figure 27: Global Next-Generation Gynecological Cancer Diagnostics, Market Dynamics Figure 28: Impact Analysis of Market Drivers and Opportunities on Global Next-Generation Gynecological Cancer Diagnostics Market Figure 29: Cost per Human Genome (2014–2021) Figure 30: Approved Number of Personalized Medicine (2016–2020) Figure 31: Percentage of Food and Drug Administration (FDA) Approved Personalized Medicines (2015– 2020) Figure 32: Next-Generation Sequencing (NGS) for Human Papillomavirus (HPV) Detection and Characterization Process Steps Figure 33: Global Next-Generation Gynecological Cancer Diagnostics Market (by Technology), 2020 and 2031 Figure 34: Global Next-Generation Gynecological Cancer Diagnostics Market (Polymerase Chain Reaction (PCR)), $Million, 2020-2031 Figure 35: Global Next-Generation Gynecological Cancer Diagnostics Market (Polymerase Chain GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET Reaction (PCR)), Thousand Units, 2020-2031 Figure 36: Global Next-Generation Gynecological Cancer Diagnostics Market (Next-Generation Sequencing (NGS)), $Million, 2020-2031 Figure 37: Global Next-Generation Gynecological Cancer Diagnostics Market (Next-Generation Sequencing (NGS)), Thousand Units, 2020-2031 Figure 38: Global Next-Generation Gynecological Cancer Diagnostics Market (by Next-Generation Sequencing (NGS), Broad Panels), $Million, 2020-2031 Figure 39: Global Next-Generation Gynecological Cancer Diagnostics Market (by Next-Generation Sequencing (NGS), Broad Panels), Thousand Units, 2020-2031 Figure 40: Global Next-Generation Gynecological Cancer Diagnostics Market (by Next-Generation Sequencing (NGS), Targeted Gene Panels), $Million, 2020-2031 Figure 41: Global Next-Generation Gynecological Cancer Diagnostics Market (by Next-Generation Sequencing (NGS), Targeted Gene Panels), Thousand Units, 2020-2031 Figure 42: Global Next-Generation Gynecological Cancer Diagnostics Market (by Next-Generation Sequencing (NGS), Single Gene Panels), $Million, 2020-2031 Figure 43: Global Next-Generation Gynecological Cancer Diagnostics Market (by Next-Generation Sequencing (NGS), Single Gene Panels), Thousand Units, 2020-2031 Figure 44: Global Next-Generation Gynecological Cancer Diagnostics Market (Other Technologies), $Million, 2020-2031 14 All rights reserved at BIS Research Inc.

  15. Figure 45: Global Next-Generation Gynecological Cancer Diagnostics Market (Other Technologies), Thousand Units, 2020-2031 Figure 46: Global Next-Generation Gynecological Cancer Diagnostics Market (by Product Type), 2020 and 2031 Figure 47: Global Next-Generation Gynecological Cancer Diagnostics Market (Services), $Million, 2020- 2031 Figure 48: Global Next-Generation Gynecological Cancer Diagnostics Market (Products), $Million, 2020- 2031 Figure 49: Global Next-Generation Gynecological Cancer Diagnostics Market (by Indication), 2020 and 2031 Figure 50: Global Next-Generation Gynecological Cancer Diagnostics Market (Ovarian Cancer), $Million, 2020-2031 Figure 51: Global Next-Generation Gynecological Cancer Diagnostics Market (Cervical Cancer), $Million, 2020-2031 Figure 52: Global Next-Generation Gynecological Cancer Diagnostics Market (Uterine Cancer), $Million, 2020-2031 GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET Figure 53: Global Next-Generation Gynecological Cancer Diagnostics Market (by End User), 2020 and 2031 Figure 54: Global Next-Generation Gynecological Cancer Diagnostics Market (Academic and Research Institutes), $Million, 2020-2031 Figure 55: Global Next-Generation Gynecological Cancer Diagnostics Market (Hospitals and Ambulatory Centers), $Million, 2020-2031 Figure 56: Global Next-Generation Gynecological Cancer Diagnostics Market (Diagnostic Laboratories), $Million, 2020-2031 Figure 57: Global Next-Generation Gynecological Cancer Diagnostics Market (Other End Users), $Million, 2020-2031 Figure 58: Global Next-Generation Gynecological Cancer Diagnostics Market (by Region) Figure 59: Global Next-Generation Gynecological Cancer Diagnostics Market (by Region), 2020-2031 Figure 60: Global Next-Generation Gynecological Cancer Diagnostics Market (by Region), $Million, 2020-2031 Figure 61: North America Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020- 2031 Figure 62: North America, Market Dynamics Figure 63: North America Next-Generation Gynecological Cancer Diagnostics Market (by Country), 2020-2031 15 All rights reserved at BIS Research Inc.

  16. Figure 64: U.S. Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031 Figure 65: Canada Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031 Figure 66: Europe Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031 Figure 67: Europe, Market Dynamics Figure 68: Europe Next-Generation Gynecological Cancer Diagnostics Market (by Country), 2020-2031 Figure 69: Germany Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031 Figure 70: U.K. Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031 Figure 71: France Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031 Figure 72: Italy Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031 Figure 73: Spain Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031 Figure 74: Netherlands Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031 Figure 75: Rest-of-Europe Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020- 2031 Figure 76: Asia-Pacific Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031 Figure 77: APAC, Market Dynamics GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET Figure 78: APAC Next-Generation Gynecological Market (by Country), 2020-2031 Figure 79: China Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031 Figure 80: Japan Next-Generation Cancer Gynecological Cancer Diagnostics Market, $Million, 2020- 2031 Figure 81: India Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031 Figure 82: Australia Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031 Figure 83: South Korea Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031 Figure 84: RoAPAC Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031 Figure 85: Latin America Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020- 2031 Figure 86: Latin America, Market Dynamics Figure 87: Latin America Next-Generation Gynecological Cancer Diagnostics Market (by Country), 2020- 2031 Figure 88: Brazil Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031 Figure 89: Mexico Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031 Figure 90: Rest-of-Latin America Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031 Figure 91: RoW Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031 16 All rights reserved at BIS Research Inc.

  17. Figure 92: Share of Key Developments and Strategies, January 2019–January 2022 Figure 93: Share of Regulatory and Legal Activities (by Company), January 2019–January 2022 Figure 94: Share of Synergistic Activities (by Company), January 2019–January 2022 Figure 95: Share of Mergers and Acquisitions (by Company), January 2019–January 2022 Figure 96: Share of Product Launches (by Company), January 2019–January 2022 Figure 97: Share of Business Expansions (by Company), January 2019–January 2022 Figure 98: Market Share Analysis for Global Next-Generation Gynecological Cancer Diagnostics Market (by Service Providers), 2020 Figure 99: Market Share Analysis for Global Next-Generation Gynecological Cancer Diagnostics Market (by Manufacturers), 2020 Figure 100: Growth Share Analysis for Global next-generation gynecological cancer diagnostics, (by Service Providers), 2020 Figure 101: Growth Share Analysis for Global next-generation gynecological cancer diagnostics, (by Product Manufacturers), 2020 Figure 102: Shares of Key Company Profiles GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET Figure 103: Agilent Technologies, Inc.: Product Portfolio Figure 104: Agilent Technologies, Inc.: Overall Financials/Revenue, $Million, 2019-2021 Figure 105: Agilent Technologies, Inc.: Revenue (by Segment), $Million, 2019-2021 Figure 106: Agilent Technologies, Inc.: Revenue (by Region), $Million, 2019-2021 Figure 107: Agilent Technologies, Inc.: R&D Expenditure, $Million, 2019-2021 Figure 108: Agilent Technologies, Inc.: SWOT Analysis Figure 109: ARUP Laboratories: Service Portfolio Figure 110: ARUP Laboratories: SWOT Analysis Figure 111: BGI Genomics: Product Portfolio Figure 112: BGI Genomics: SWOT Analysis Figure 113: CENTOGENE N.V.: Service Portfolio Figure 114: CENTOGENE N.V.: Overall Financials/Revenue, $Million, 2018-2020 Figure 115: CENTOGENE N.V.: Revenue (by Business Segment), $Million, 2018-2020 Figure 116: CENTOGENE N.V.: Revenue (by Region), $Million, 2018-2020 Figure 117: CENTOGENE N.V.: R&D Expenditure, $Million, 2018-2020 Figure 118: CENTOGENE N.V.: SWOT Analysis Figure 119: F. Hoffmann-La Roche Ltd: Product Portfolio Figure 120: F. Hoffmann-La Roche Ltd: Overall Financials/Revenue, $Billion, 2019-2021 17 All rights reserved at BIS Research Inc.

  18. Figure 121: F. Hoffmann-La Roche Ltd: Revenue (by Segment), $Billion, 2019-2021 Figure 122: F. Hoffmann-La Roche Ltd: Revenue (by Region), $Billion, 2019-2021 Figure 123: F. Hoffmann-La Roche Ltd: R&D Expenditure, $Billion, 2019-2021 Figure 124: F. Hoffmann-La Roche Ltd: SWOT Analysis Figure 125: Fulgent Genetics, Inc.: Service Portfolio Figure 126: Fulgent Genetics, Inc.: Overall Financials/Revenue, $Million, 2018-2020 Figure 127: Fulgent Genetics, Inc.: Revenue (by Region), $Million, 2018-2020 Figure 128: Fulgent Genetics, Inc.: R&D Expenditure, $Million, 2018-2020 Figure 129: Fulgent Genetics, Inc.: SWOT Analysis Figure 130: Illumina, Inc.: Product Portfolio Figure 131: Illumina, Inc.: Overall Financials/Revenue, $Million, 2018-2020 Figure 132: Illumina, Inc.: Revenue (by Business Segment), $Million, 2018–2020 Figure 133: Illumina, Inc.: Revenue (by Region), $Million, 2018–2020 Figure 134: Illumina, Inc.: R&D Expenditure, $Million, 2018-2020 Figure 135: Illumina, Inc.: SWOT Analysis GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET Figure 136: Invitae Corporation: Service Portfolio Figure 137: Invitae Corporation: Overall Financials/Revenue, $Million, 2018-2020 Figure 138: Invitae Corporation: Revenue (by Business Segment), $Million, 2018–2020 Figure 139: Invitae Corporation: Revenue (by Region), $Million, 2018-2020 Figure 140: Invitae Corporation: R&D Expenditure, $Million, 2018-2020 Figure 141: Invitae Corporation: SWOT Analysis Figure 142: Konica Minolta, Inc.: Service Portfolio Figure 143: Konica Minolta, Inc.: Overall Financials/Revenue, $Million, 2018-2020 Figure 144: Konica Minolta, Inc.: Revenue (by Business Segment), $Million, 2019-2020 Figure 145: Konica Minolta, Inc.: Revenue (by Healthcare Business), $Million, 2019-2020 Figure 146: Konica Minolta, Inc.: Revenue (by Region), $Million, 2018-2020 Figure 147: Konica Minolta, Inc.: R&D Expenditure, $Million, 2018-2020 Figure 148: Konica Minolta, Inc.: SWOT Analysis Figure 149: Laboratory Corporation of America Holdings: Service Portfolio Figure 150: Laboratory Corporation of America Holdings: Overall Financials/Revenue, $Million, 2018-2020 Figure 151: Laboratory Corporation of America Holdings: Revenue (by Segment), $Million, 2018-2020 Figure 152: Laboratory Corporation of America Holdings: Revenue (by Region), $Million, 2018-2020 Figure 153: Laboratory Corporation of America Holdings: SWOT Analysis 18 All rights reserved at BIS Research Inc.

  19. Figure 154: Myriad Genetics, Inc.: Service Portfolio Figure 155: Myriad Genetics, Inc.: Overall Financials/Revenue, 2018-2020 Figure 156: Myriad Genetics, Inc.: Revenue (by Business Segment), 2018-2020 Figure 157: Myriad Genetics, Inc.: SWOT Analysis Figure 158: OPKO Health, Inc.: Service Portfolio Figure 159: OPKO Health, Inc.: Overall Financials/Revenue, $Million, 2018-2020 Figure 160: OPKO Health, Inc.: Revenue (by Business Segment), $Million, 2018–2020 Figure 161: OPKO Health, Inc.: Revenue (by Region), $Million, 2018-2020 Figure 162: OPKO Health, Inc.: R&D Expenditure, $Million, 2018-2020 Figure 163: OPKO Health: SWOT Analysis Figure 164: QIAGEN N.V.: Product Portfolio Figure 165: QIAGEN N.V.: Overall Financials/Revenue, 2019-2021 Figure 166: QIAGEN N.V.: Revenue (by Segment), 2019-2021 Figure 167: QIAGEN N.V.: Revenue (by Region), 2019-2021 Figure 168: QIAGEN N.V.: R&D Expenditure, 2019-2021 GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET Figure 169: QIAGEN N.V.: SWOT Analysis Figure 170: Quest Diagnostics Incorporated: Service Portfolio Figure 171: Quest Diagnostics Incorporated: Overall Financials/Revenue, $Million, 2018-2020 Figure 172: Quest Diagnostics Incorporated: Revenue (by Business Segment), $Million, 2018-2020 Figure 173: Quest Diagnostics Incorporated: SWOT Analysis Figure 174: Thermo Fisher Scientific Inc.: Product Portfolio Figure 175: Thermo Fisher Scientific Inc.: Overall Financials, $Million, 2018-2020 Figure 176: Thermo Fisher Scientific Inc.: Revenue (by Business Segment), $Million, 2018–2020 Figure 177: Thermo Fisher Scientific Inc.: Revenue (by Region), $Million, 2018–2020 Figure 178: Thermo Fisher Scientific Inc.: R&D Expenditure, $Million, 2018-2020 Figure 179: Thermo Fisher Scientific Inc.: SWOT Analysis Figure 180: NgeneBio: Product Portfolio Figure 181: oncgnostics GmbH: Product Portfolio Figure 182: Self-screen B.V.: Product Portfolio Figure 183: Strata Oncology, Inc.: Product Portfolio 19 All rights reserved at BIS Research Inc.

  20. List of Tables Table 1: Risks Associated with the Types of Genes Related to Hereditary Ovarian and Uterine Cancer Table 2: Advantages and Limitations of Short-Read Sequencing and Long-Read Sequencing Table 3: National Comprehensive Cancer Network (NCCN) Recommended Predictive Molecular Testing in Gynecological Cancer Table 4: Food and Drug Administration (FDA) Approved Companion Diagnostics (CDx) for Gynecological Cancers Table 5: Reimbursement Scenario Across Major Countries Table 6: Regulatory Framework and Reimbursement Options of NGS-Based Diagnostics Across Major Countries Table 7: Next-Generation Sequencing Clinical Utility in Gynecological Cancers Table 8: Services Offered by Key Players Table 9: Products Offered by Key Players GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET 20 All rights reserved at BIS Research Inc.

  21. BIS Research Offerings: We are on a mission to harness the potential of disruptive technologies to make businesses thrive in today’s digital age. We have a vision to be a leading and a preferred knowledge partner for corporates and institutions worldwide and assist them with market intelligence in the area of emerging technologies, advisories, and other innovative solutions. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET Know More Know More Know More Know More 21 All rights reserved at BIS Research Inc.

  22. Disclaimer BIS Research Inc. provides valuable market intelligence to an exclusive group of customers in response to orders. The report is licensed for the customer's internal use only and is subject to restrictions set henceforth. This document and its contents are confidential and may not be further distributed, published or reproduced, in whole or in part, by any medium or in any form for any purpose, without the express written consent of BIS Research Inc. Customer will not disclose the contents of the report, whether directly in any media or indirectly through incorporation in a database, marketing list, report or otherwise, or use or permit the use of Information to generate any statistical or other information that is or will be provided to third parties; or voluntarily produce Information in legal proceedings. Market reports are based on expectations, estimates and projections as of the date such information is available. Any recommendation contained in this report may not be suitable for all investors or businesses. The market conclusions drawn are necessarily based upon a number of estimates and assumptions that, while considered reasonable by BIS Research Inc. as of the date of such statements, are inherently subject to market fluctuations and business, economic and competitive uncertainties, and contingencies GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET For more details regarding permission, please contact us: Email: sales@bisresearch.com Tel: +1 510 404 8135 22 All rights reserved at BIS Research Inc.

  23. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET BIS RESEARCH INC. 39111 Paseo Padre PKWY, Suite 313 Fremont, CA 94538 -1686 E-mail: hello@bisresearch.com | Call Us: +1-510-404-8135 Global Delivery Center Tower B First Floor, Tapasya Corporate Heights, Greater Noida Expressway, Sector 126, Noida, U.P., 201303, India Tel: +91 120 4261540 / 4261544 www.bisresearch.com 23 All rights reserved at BIS Research Inc.

More Related